Suppr超能文献

对临床试验中迷幻药治疗临床进展的快速叙述性综述。

A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.

作者信息

Kishon Ronit, Modlin Nadav Liam, Cycowicz Yael M, Mourtada Hania, Wilson Tayler, Williamson Victoria, Cleare Anthony, Rucker James

机构信息

Department of Psychiatry, Columbia University, New York, NY, USA.

New York State Psychiatric Institute, New York, NY, USA.

出版信息

Npj Ment Health Res. 2024 Jul 2;3(1):33. doi: 10.1038/s44184-024-00068-9.

Abstract

Pre-prohibition psychedelic research with complex psychiatric patients generated a wealth of treatment methodologies and practices, providing invaluable clinical insights pertaining to the medical administration of psychedelics in various mental health diagnoses. Building upon these early studies, which lack the rigor and research tools available today, contemporary psychedelic research has focused on investigating the safety and efficacy of psychedelics in randomized controlled trials via psychometric measures and symptom assessments. Both then and now, the treatment context and the role of clinicians in psychedelic treatment has been recognized as an essential feature for positive patient outcomes. To broaden the knowledge base of modern psychedelic research and support the training of clinicians conducting medically supervised psychedelic research studies, this paper provides a review of pre-prohibition clinical research narratives pertaining to the phenomenology of psychedelic treatment and the role of the non-pharmacological treatment factors in the patient experience. Lastly, this paper explores a range of clinician perspectives and psychological interventions employed in pre-prohibition psychedelic research to inform future research directions and best practice guidelines.

摘要

对复杂精神病患者进行的禁酒前迷幻剂研究产生了丰富的治疗方法和实践,为各种精神健康诊断中迷幻剂的医学管理提供了宝贵的临床见解。基于这些早期研究(这些研究缺乏当今可用的严谨性和研究工具),当代迷幻剂研究专注于通过心理测量方法和症状评估在随机对照试验中研究迷幻剂的安全性和有效性。无论是当时还是现在,治疗背景以及临床医生在迷幻剂治疗中的作用都被认为是患者取得积极治疗效果的一个基本特征。为了拓宽现代迷幻剂研究的知识基础,并支持对进行医学监督下迷幻剂研究的临床医生的培训,本文回顾了禁酒前关于迷幻剂治疗现象学以及非药物治疗因素在患者体验中的作用的临床研究叙述。最后,本文探讨了禁酒前迷幻剂研究中一系列临床医生的观点和采用的心理干预措施,以为未来的研究方向和最佳实践指南提供参考。

相似文献

1
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.
Npj Ment Health Res. 2024 Jul 2;3(1):33. doi: 10.1038/s44184-024-00068-9.
2
5
Psychedelic therapy in the treatment of addiction: the past, present and future.
Front Psychiatry. 2023 Jun 12;14:1183740. doi: 10.3389/fpsyt.2023.1183740. eCollection 2023.
6
The psychedelic effects of cannabis: A review of the literature.
J Psychopharmacol. 2024 Jan;38(1):49-55. doi: 10.1177/02698811231209194. Epub 2023 Nov 10.
7
8
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Psychologists' and psychotherapists' knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics.
Clin Psychol Psychother. 2023 Nov-Dec;30(6):1369-1379. doi: 10.1002/cpp.2880. Epub 2023 Jul 2.
10
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.
ACS Pharmacol Transl Sci. 2021 Mar 11;4(2):436-451. doi: 10.1021/acsptsci.1c00024. eCollection 2021 Apr 9.

引用本文的文献

1
The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches.
Front Immunol. 2025 Jun 12;16:1595977. doi: 10.3389/fimmu.2025.1595977. eCollection 2025.
2
Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.
Front Psychol. 2025 Mar 4;16:1528253. doi: 10.3389/fpsyg.2025.1528253. eCollection 2025.
3
Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.
Pharmaceuticals (Basel). 2025 Jan 19;18(1):130. doi: 10.3390/ph18010130.

本文引用的文献

1
Call for evidence-based psychedelic integration.
Exp Clin Psychopharmacol. 2024 Apr;32(2):129-135. doi: 10.1037/pha0000684. Epub 2023 Nov 27.
2
History repeating: guidelines to address common problems in psychedelic science.
Ther Adv Psychopharmacol. 2023 Sep 25;13:20451253231198466. doi: 10.1177/20451253231198466. eCollection 2023.
3
Neuroimaging in psychedelic drug development: past, present, and future.
Mol Psychiatry. 2023 Sep;28(9):3573-3580. doi: 10.1038/s41380-023-02271-0. Epub 2023 Sep 27.
4
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Nat Med. 2023 Oct;29(10):2473-2480. doi: 10.1038/s41591-023-02565-4. Epub 2023 Sep 14.
5
Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts.
J Psychoactive Drugs. 2023 Nov-Dec;55(5):558-569. doi: 10.1080/02791072.2023.2255274. Epub 2023 Sep 7.
6
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
JAMA. 2023 Sep 5;330(9):843-853. doi: 10.1001/jama.2023.14530.
7
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Neuropsychopharmacology. 2024 Jan;49(1):96-103. doi: 10.1038/s41386-023-01656-7. Epub 2023 Jul 21.
8
Must Psilocybin Always "Assist Psychotherapy"?
Am J Psychiatry. 2024 Jan 1;181(1):20-25. doi: 10.1176/appi.ajp.20221043. Epub 2023 Jul 12.
9
The down-scheduling of MDMA and psilocybin(e): Too fast and too soon.
Aust N Z J Psychiatry. 2023 Jul;57(7):933-934. doi: 10.1177/00048674231174171. Epub 2023 May 10.
10
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.
J Affect Disord. 2023 Apr 1;326:18-25. doi: 10.1016/j.jad.2023.01.077. Epub 2023 Jan 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验